Meeting
2023 ASCO Annual Meeting
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
Authors
D. Ross Camidge
University of Colorado Cancer Center, Aurora, CO
D. Ross Camidge , Shunichi Sugawara , Masashi Kondo , Hye Ryun Kim , Myung-Ju Ahn , James Chih-Hsin Yang , Ji-Youn Han , Maximilian J. Hochmair , Ki Hyeong Lee , Angelo Delmonte , Kentarou Kudou , Takayuki Asato , Yuyin Liu , Florin Vranceanu , Robert J. Fram , Yuichiro Ohe , Sanjay Popat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02737501; NCT03410108
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9078)
DOI
10.1200/JCO.2023.41.16_suppl.9078
Abstract #
9078
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
First Author: Vineeth Tatineni
Poster
2019 ASCO Annual Meeting
Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
First Author: Salvatore Siena
First Author: Marcello Tiseo
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse